근감소증, 표적항암제, BCR-ABL, T315I, RET, FGFR4, KIT, CSF1R, sarcopenia, targeted cancer agents
Investors 5
| Date | Name | Website |
| - | Quantum Ve... | quantumepk... |
| - | AJU IB Inv... | ajuib.co.k... |
| - | we venture... | en.weventu... |
| - | IMM Invest... | imminvestm... |
| - | Company K ... | kpartners.... |
Mentions in press and media 1
| Date | Title | Description |
| 29.10.2021 | ImmunoForge Inc. receives U.S. FDA ODD for PF1801 | SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire/ -- ImmunoForge (Co-CEOs Sung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug cand... |